Mutations in BRAF, RET/PTC, NTRK1, or RAS have been reported in up to 70% of differentiated thyroid cancers [18,19] and historically it does not depend on an MMR deficiency [20,21,22,23]. This evidence concerns the gene RET and thyroid gland carcinoma.